Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 3/20 | 0.33 |
| ▸ | BRAF | P15056 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20361662 | 1.00 | KCNH2 (0.55) | KCNH2SLCO1B1NR1I2RAF1BRAF | |
| SCHEMBL21714899 | 0.96 | KCNH2 (0.60) | KCNH2SLCO1B1NR1I2RAF1BRAF | |
| SCHEMBL20372284 | 0.96 | KCNH2 (0.60) | KCNH2SLCO1B1NR1I2RAF1BRAF | |
| SCHEMBL20361070 | 0.92 | KCNH2 (0.66) | KCNH2SLCO1B1NR1I2RAF1BRAF | |
| SCHEMBL21595831 | 0.92 | KCNH2 (0.56) | KCNH2SLCO1B1NR1I2RAF1BRAF | |
| SCHEMBL21734288 | 0.92 | KCNH2 (0.66) | KCNH2SLCO1B1NR1I2RAF1BRAF | |
| SCHEMBL21714822 | 0.92 | KCNH2 (0.52) | KCNH2SLCO1B1NR1I2RAF1 | |
| SCHEMBL20360973 | 0.92 | KCNH2 (0.52) | KCNH2SLCO1B1NR1I2RAF1 | |
| SCHEMBL21734289 | 0.91 | KCNH2 (0.58) | KCNH2SLCO1B1NR1I2RAF1BRAF | |
| SCHEMBL20361985 | 0.91 | KCNH2 (0.58) | KCNH2SLCO1B1NR1I2RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055839-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055839-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DUT | KCNH2 3952/4885SLCO1B1 1430/4885NR1I2 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.